Aprea Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
Provided By GlobeNewswire
Last update: Nov 7, 2024
Preliminary results from Phase 1 ACESOT-1051 trial of WEE1 inhibitor, APR-1051, demonstrate the product to be well-tolerated with no unexpected toxicities
Philippe Pultar, MD engaged as senior medical advisor to support the development and advancement of APR-1051
Read more at globenewswire.com
